 |
Arginetix, Inc. is
a biopharmaceutical company dedicated to developing and commercializing novel therapeutic Arginase inhibitors. Elevation of Arginase enzyme levels is associated with endothelial dysfunction, and has been shown to reduce Nitric Oxide
(NO) production and increase the production of damaging reactive oxygen species (ROS). |
| |
|
|
Avid Radiopharmaceuticals is developing new molecular imaging agents capable of changing the medical management of significant chronic human diseases; allowing early treatment and management of people at risk - before symptoms of disease can develop. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease, and Diabetes Mellitus. |
| |
|
|
CancerGuide is a groundbreaking discovery from Duke University to apply gene expression profiling of tumors to choose the best standard of care for cancer patients. |
| |
|
 |
Gevo, Inc. is
dedicated to being the world leader in the development and commercialization of advanced bio-fuels, the new generation of bio-based fuels and related products that are specifically designed to meet the full needs of stakeholders, consumers, and the industry. |
| |
|
|
Kolltan Pharmaceuticals, Inc. develops therapeutic monoclonal antibodies for the treatment of cancer based on seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at Yale University. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of receptor tyrosine kinases (RTKs) providing, for the first time, a clear molecular explanation – at atomic resolution – for the oncogenic activity of mutations that have been identified in a variety of human cancers. |
| |
|
|
Luxtera, Inc. is a fabless Silicon Photonics company with a unique technology platform to manufacture a new breed of monolithic opto-electronic devices in a low cost CMOS process. Luxtera’s CMOS Photonics™ devices are fully integrated with CMOS electronics and are orders of magnitude smaller (and often faster) than traditional photonic elements. The company’s vision is to deliver economic optical connectivity everywhere, from network level to intra-system level, and eventually chip-to-chip. |
| |
|
|
MC10, Inc. is developing electronic circuits that can stretch up to 400% with wide-ranging applications in medical devices, sensors, and compact cameras. The technology was developed by Prof. John Rogers at University of Illinois, Urbana-Champaign, while the medical applications were developed in collaboration with researchers at University of Pennsylvania. MC10’s technology has been covered by The Wall Street Journal, NY Times, Nature, BBC, MSNBC, etc, and has been billed by MIT’s Technology Review as “one of the 10 technologies that will change the world”.
|
| |
|
|
|
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Virdante utilizes proprietary “sialic switch” technology to improve the anti-inflammatory properties of antibodies. |
